###### Strengths and limitations of this study

-   This meta-analysis evaluated the diagnostic capability of *Wisteria floribunda* agglutinin-sialylated Mucin1 (WFA-MUC1) and prognostic role of Mucin1 (MUC1) in cholangiocarcinoma.

-   The diagnostic capability of WFA-MUC1 is superior to that of CA19-9.

-   The diagnostic capability of WFA-MUC1 in bile is better that in serum.

-   Expression of MUC1 in biliary duct cancer tissues is a prognosis factor for poor outcomes of resectable cholangiocarcinoma.

-   Majority of the subjects included in this meta-analysis were from Asia. More participants from different regions other than Asia are needed to better evaluate the roles of Mucin1 in the diagnosis and prognosis of cholangiocarcinoma worldwide.

Introduction {#s1}
============

Cholangiocarcinoma (CCA) is a malignancy arising from epithelia at various anatomic locations in the biliary tree.[@R1] The median survival time for patients with unresectable CCA is less than a year.[@R2] The prognosis is considerably better for CCA patients who underwent radical resection, with a 5-year survival rates ranging from 20% to 40%.[@R4] However, it is hard to detect CCA at the early stage, even with the advanced imaging technology and the complete diagnosis protocol currently. This situation limits the benefits of surgery therapy and curative treatment options to CCA patients and contributes to the poor outcome of patients with CCA.

Currently, a huge amount of literature reporting numerous molecular biomarkers with limited diagnostic or prognostic capability for CCA have been published. Some of the reported biomarkers have been used for guiding clinical diagnosis and treatment of CCA worldwide, such as Mucin2 to Mucin6,[@R6] carbohydrate antigen 19-9 (CA19-9),[@R16] interleukin-6,[@R19] serum cytokeratin 19 fragments[@R21] and carbohydrate antigen 125.[@R16] Among these biomarkers, CA19-9 in serum has been the focus of related research and always been used as a biomarker for CCA. However, the overall sensitivity and specificity of CA19-9 is not satisfying, and CA19-9 is not capable of detecting CCA progression.[@R5] In addition, although CA19-9 expression is elevated in up to 85% suspected CCA,[@R17] the capability of CA19-9 as a diagnostic marker is still limited due to influence of coexisting inflammation in biliary tract and the fact that cancer cells from Lewis gene negative subtype of CCA does not produce CA19-9 theoretically.[@R17]

Mucin1 (MUC1), also known as polymorphic epithelial Mucin, is cell surface associated and belongs to Mucin family. It is a mucin encoded by the MUC1 gene in humans.[@R28] MUC1 is a high molecular weight, membrane-associated glycoprotein with a 69 amino acids cytoplasmic tail, a transmembrane domain and an extracellular domain consisting of a variable number of highly conserved tandem repeats of 20 amino acids.[@R28] Highly glycosylated MUC1 has been reported to be associated with malignancies in many other organs.[@R30] Matsuda *et al* [@R31] reported that *Wisteria floribunda* agglutinin-sialylation (WFA) could be employed as the best probe to detect alterations of glycan structure in biliary tract-derived cancer cells and distinguish it from normal tissues. They also identified sialylated MUC1 as a potential CCA-specific glycoprotein marker. From then on, *Wisteria floribunda* agglutinin sialylated-Mucin1 (WFA-MUC1) has been regarded as a sensitive molecular biomarker for CCA.[@R9] However, the diagnostic capability of WFA-MUC1 remains unclear since the reported range of WFA-MUC1 distinguishing CCA from benign biliary diseases varied greatly (0.74\~0.87 in serum, 0.72\~0.90 in bile).[@R9] In addition, although the correlation between the expression of MUC1 in biliary duct-derived cancer and the overall survival (OS) rate for patients with resectable CCA has been analysed with Kaplan-Meier plot in several clinical trials, the result still remains inconclusive. Besides, more questions about MUC1 in CCA still need to be answered such as whether expression of MUC1 suggests a poor prognosis for patients with CCA and whether expression level of MUC1 associates with CCA progression.[@R7]

Therefore, we conducted this meta-analysis to evaluate the diagnostic capability of WFA-MUC1 in discriminating patients with CCA from benign biliary diseases and to investigate the prognostic role of MUC1 in patients with CCA.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

The initial comprehensive literature search through 11 March 2017 was performed in database of PubMed, Web of Science, The Cochrane Library and the China National Knowledge Infrastructure. Our latest search was completed on 11 October 2017. The publication language was restricted to articles published in English or Chinese. Searching keywords used are 'Wisteria floribunda agglutinin sialylated-mucin1(WFA-MUC1)', 'Mucin1/MUC1', 'cholangiocarcinoma/CCA', 'cholangiocellular carcinoma', 'intrahepatic cholangiocarcinoma', 'extrahepatic cholangiocarcinoma' or 'Klatskin tumor/hilar cholangiocarcinoma/perihilar cholangiocarcinoma' combined with 'prognosis/prognostic/prognoses/survival' or 'diagnosis/diagnostic/diagnoses'. The reference lists of every study that met the inclusion criteria were also manually reviewed to identify additional relevant publications.

Patient and public involvement {#s2b}
------------------------------

Patients and public were not involved as all the data used have been published previously and hence are already in the public domain.

Eligibility criteria {#s2c}
--------------------

Published studies were included if they met the following criteria: (1) the published studies were focused on CCA; (2) all studied subjects with CCA were diagnosed by pathologist postoperatively; (3) the expression of MUC1 in tissues was detected by immunohistochemistry staining and the level of WFA-MUC1 in bile or serum was tested by sandwich ELISA; (4) the receiver operating characteristic curve (ROC) of WFA-MUC1 and/or CA19-9 was described and the rates of true positives, false positives, false negatives and true negatives can be calculated; and (5) the HRs including 95% CI and the corresponding p value can be extracted. Studies were excluded based on following criteria: (1) animal studies; (2) review articles, case reports or letters; (3) duplicated publication; (4) non-English or non-Chinese papers; and (5) insufficient data on the HRs or that could not be extracted from Kaplan-Meier analysis result.

Data extraction {#s2d}
---------------

Data extraction was carried out by two investigators independently (ZT and YY). If discrepancies occurred, it would be resolved by the consensus of these two investigators. Data related to the study characteristics were extracted with the following variables: the first author of the study, study design and duration, year of publication, institution, the number of subjects in the study with mean age and gender, the selected antibody for the MUC1 immunochemical staining, ELISA assay kits testing the level of biliary and/or serum WFA-MUC1 and the level of serum CA-19--9, the area under the curve (AUC) for WFA-MUC1, the cut-off value of MUC1, assay's sensitivity and specificity, HRs and their 95% CI and case follow-up time. For the three studies that did not provide the value of HRs and their 95% CI, we digitised and extracted the data from the Kaplan-Meier curve in the publications by using the software designed by Jayne F Tierney and Matthew R Sydes.[@R38] The optimal sensitivity and specificity were reported graphically in one study with two cohorts and were extracted using Plot Digitizer software V.2.6.8 (provided by source forge.net, found online at [http://plot digitizer source forge.net/](http://plot%20digitizer%20source%20forge.net/)) to convert data points on the graphs into numerical data.[@R39] Repeated data points were isolated using non-parametric bootstrap sampling[@R41] guided by the descriptive statistics provided in the supporting document. The possible repeated data points were repeatedly sampled until the sets matching the descriptive statistics was found. All the data were extracted from published literature.

Quality assessment across studies {#s2e}
---------------------------------

Quality assessment of the studies in the prognostic meta-analysis was performed by using the modified risk of bias tool recommended by the Cochrane Collaboration as described previously.[@R42] Quality assessment of studies evaluating the diagnostic capability of WFA-MUC1 was performed using the Quality Assessment of Studies of Diagnostic Accuracy included in Systematic reviews (QUADAS) checklists.[@R45] However, we did not calculate the summary scores for each study investigating the diagnostic capability of WFA-MUC1 because their interpretation was problematic and because their report was potentially misleading.[@R47] Moreover, seven of the best differentiating items have been selected from the QUADAS checklists.

Statistical analyses {#s2f}
--------------------

The statistical analysis was performed according to the guidelines proposed by the Meta-Analysis of Observational Studies in Epidemiology group.[@R48] The pooled HRs with 95% CI were calculated with a random-effect model according to the DerSimonian-Laird method to evaluate the correlation between the positive expression of MUC1 and OS.[@R49] Sensitivity and specificity for each study evaluating the diagnostic capability of WFA-MUC1 were calculated and analysed this datum as bivariate data according to methods for diagnostic meta-analysis.[@R51] An aggregated bivariate data meta-analysis with the generation of forest plots and summary ROC (SROC) was performed. Forest plots displayed the diagnostic probabilities of individual studies, the corresponding 95% CI and squares with area proportional to study weight in the meta-analysis. The SROC demonstrated individual study data point with circles, with size proportion to study weight and 95% prediction contour and 95% confidence contour around the pooled estimate. The heterogeneity among studies was measured using the Q tests and I^2^ statistic to assess the extent of the inconsistency. A probability value of p\<0.1 and I^2^\>50% indicated the existence of significant heterogeneity.[@R52] Furthermore, funnel plot and the Egger's linear regression test were applied to evaluate potential publication bias for eligible studies using OS as an endpoint.[@R53] A p\<0.1 for Egger's test was considered statistically significant. All statistical analyses were performed with Stata/MP V.14.0.

Results {#s3}
=======

Study selection {#s3a}
---------------

The study includes results of electronic searches up to 11 October 2017. A total of 341 papers were identified, of which 148 were retrieved for full-text review. Among these 148 publications, 16 studies[@R6] were eligible for the meta-analyses according to the inclusion and exclusion criteria. Nine studies[@R7] out of 16 studies used OS as endpoint, and eight studies[@R6] used the sensitivity and specificity rate as the endpoint (one study reported by Huang *et al* also provided the data on diagnostic value of MUC1 in tissue). The detailed literature searching process was shown in [figure 1](#F1){ref-type="fig"}.

![Diagram showing the literature searching work flow.](bmjopen-2018-021693f01){#F1}

Characteristics of the included studies and participants {#s3b}
--------------------------------------------------------

Characteristics of eligible studies and their participants were listed in [tables 1](#T1){ref-type="table"}, [table 2](#T2){ref-type="table"} and [table 3](#T3){ref-type="table"}. A total of nine studies[@R7] evaluating the prognostic value of MUC1 for resectable CCA were conducted in four countries (Korea, Japan, China and Thailand), the other seven studies[@R6] investigating the diagnostic capability of WFA-MUC1 were undertaken in five countries (Japan, UK, Brazil, Thailand and China). Retrospective study design was applied to perform the meta-analysis of prognostic value by all selected studies. The seven studies investigating the diagnostic capability of WFA-MUC1, meaning that discriminating CCA from benign biliary diseases, used prospective study design. All CCA diagnosis included in this study were based on histopathology as reported in the include publications. The sample size of eligible studies evaluating the prognostic value of MUC1 varied greatly, ranging from 27 to 87 with a median size of 56. The sample size of studies investigating the diagnostic capability of WFA-MUC1 ranged from 30 to 303 (median=80) and from 20 to 287 (median=69) for biliary tract carcinoma group and benign biliary diseases group, respectively.

###### 

Characteristics of studies included in this meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                     Year   Country      No. of BTC   No. of BBD   Mean age           Male/female         Type of BTC   Specimen source   Association   Study design                                                                     
  -------------------------- ------ ------------ ------------ ------------ ------------------ ------------------- ------------- ----------------- ------------- ---------------- ------------------------- -------- ---------------- ----------- ---
  Shoda *et al* [@R35]       2017   Japan        303          287          71 (33--101)       68 (19--92)         193/110       153/134           59            117              71                        59       Bile and serum   Diagnosis   P

  Yamaguchi *et al* [@R34]   2016   Japan        174          27           69 (36--85)        64 (27--82)         108/66        19/8              9             133              18                        14       Bile and serum   Diagnosis   P

  Matsuda *et al* [@R55]     2015   Thailand\    78           78           56±8.25 (57--90)   54±10.42 (32--73)   23/55         23/55             CCA           Plasma           Diagnosis                 P                                     
                                    (cohort 1)                                                                                                                                                                                                   

  Matsuda *et al* [@R55]     2015   Japan\       33           40           77±8.25 (57--90)   76±9.50 (56--93)    20/13         19/21             28            1                4                         0        Serum            Diagnosis   P
                                    (cohort 2)                                                                                                                                                                                                   

  Zen *et al* [@R54]         2014   UK           28           20           67 (42--83)        61 (38--77)         17/11         15/5              28            0                0                         0        Tissue           Diagnosis   R

  Esperança *et al* [@R6]    2014   Brazil       11           67           NA                 NA                  NA            NA                CCA           Tissue           Diagnosis                 R                                     

  Matsuda *et al* [@R32]     2013   Japan        29           29           NA                 --                  NA            --                CCA           Bile and serum   Diagnosis                 P                                     

  Higashi *et al* [@R7]      2012   Japan        63           --           67.4 (41--85)      --                  33/30         --                iCCA          Tissue           Prognosis                 R                                     

  Huang *et al* [@R9]        2010   China        33           32           56.41±13.14\       55.41±13.45\        18/15         17/15             iCCA          Tissue           Prognosis and diagnosis   R                                     
                                                                           (32-75)            (33-77)                                                                                                                                            

  Matsuda *et al* [@R31]     2010   Japan        30           38           NA                 NA                  NA            NA                iCCA          Bile             Diagnosis                 P                                     

  Park *et al* [@R10]        2009   Korea        85           --           63.8 (44--82)      --                  58/27         --                34            51               0                         Tissue   Prognosis        R           

  Boonla *et al* [@R12]      2005   Thailand     87           --           56.7±8.6\          --                  59/28         --                iCCA          Tissue           Prognosis                 P                                     
                                                                           (36-73)                                                                                                                                                               

  Shibahara *et al* [@R13]   2004   Japan        27           --           65.3 (45--79)      --                  16/11         --                iCCA          Tissue           Prognosis                 R                                     

  Matsumura *et al* [@R15]   2002   Japan        50           --           60.3±10.3\         --                  33/17         --                iCCA          Tissue           Prognosis                 R                                     
                                                                           (30-75)                                                                                                                                                               

  Tamada *et al* [@R14]      2002   Japan        60           --           61.9 (41--88)      --                  41/19         --                CCA           Tissue           Prognosis                 R                                     

  Higashi *et al* [@R36]     1999   Japan        39           --           NA                 --                  --            --                30            0                7                         0        Tissue           Prognosis   R

  Takao *et al* [@R37]       1999   Japan        73           --           65.9 (39--85)      --                  50/23         --                0             37               36                        0        Tissue           Prognosis   R
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BBD, benign biliary tract diseases; BTC, biliary tract carcinoma; CCA, cholangiocarcinoma; dCCA, distal cholangiocarcinoma; GC, gallbladder carcinoma; iCCA, intrahepatic cholangiocarcinoma; NA, not available; P, prospective; pCCA perihilar cholangiocarcinoma; R, retrospective.

###### 

Characteristics of studies included in the diagnostic meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                                                                     Year   country               Optimal Se   Optimal Sp   Reference standard   Antibody            AUC     Cut-off value      TP    FP   TN    FN
  ---------------------------------------------------------------------------------------------------------- ------ --------------------- ------------ ------------ -------------------- ------------------- ------- ------------------ ----- ---- ----- ----
  2.1. Characteristics of eligible studies evaluating the diagnostic accuracy of WFA-MUC1 in serum samples                                                                                                                                               

   Shoda *et al* [@R35]                                                                                      2017   Japan                 0.776        0.780        Histopathology       WFA-MY.1E12         0.873   214.2 µL/mL        235   64   223   68

   Matsuda *et al* [@R55]                                                                                    2015   Thailand (cohort 1)   0.722        0.748        Histopathology       WFA-MY.1E12         0.841   NA                 56    16   62    22

   Matsuda *et al* [@R55]                                                                                    2015   Japan\                0.766        0.643        Histopathology       WFA-MY.1E12         0.738   NA                 25    19   21    8
                                                                                                                    (cohort 2)                                                                                                                           

  2.2. Characteristics of eligible studies evaluating the diagnostic accuracy of CA19-9 in serum samples                                                                                                                                                 

   Shoda *et al* [@R35]                                                                                      2017   Japan                 0.713        0.711        Histopathology       CA19-9 ELISA Kits   0.753   27.6 U/mL          216   83   204   87

   Yamaguchi *et al* [@R34]                                                                                  2016   Japan                 0.603        0.889        Histopathology       NA                  0.761   38 U/mL            105   3    24    69

   Matsuda *et al* [@R55]                                                                                    2015   Thailand\             0.743        0.887        Histopathology       CA19-9 ELISA kits   0.849   NA                 58    8    70    20
                                                                                                                    (cohort 1)                                                                                                                           

   Matsuda *et al* [@R55]                                                                                    2015   Japan\                0.637        0.896        Histopathology       CA19-9 ELISA kits   0.759   NA                 21    4    36    12
                                                                                                                    (cohort 2)                                                                                                                           

  2.3. Characteristics of eligible studies evaluating the diagnostic accuracy of MUC1 in bile samples                                                                                                                                                    

   Shoda *et al* [@R35]                                                                                      2017   Japan                 0.863        0.765        Histopathology       MY.1E12 (mAb)       0.896   13.5 nL/µg         158   27   88    25

   Yamaguchi *et al* [@R34]                                                                                  2016   Japan                 0.822        0.556        Histopathology       WFA-MY.1E12         0.715   10.5 nL/µg         143   12   15    31

   Matsuda *et al* [@R32]                                                                                    2013   Japan                 0.90         0.72         Histopathology       WFA-MY.1E12         0.85    7 nL/µg            26    8    21    3

   Matsuda *et al* [@R31]                                                                                    2010   Japan                 0.90         0.763        Histopathology       WFA-MY.1E12         0.86    6.64 nL/µg         27    9    29    3

  2.4. Characteristics of eligible studies evaluating the diagnostic accuracy of MUC1 in tissue samples                                                                                                                                                  

   Zen *et al* [@R54]                                                                                        2014   UK                    0.71         0.85         Histopathology       Clone DF3           --      \>5% (positive)    20    3    17    8

   Esperança *et al* [@R6]                                                                                   2014   Brazil                0.909        0.925        Histopathology       Clone Ma695         --      \>10% (positive)   10    5    62    1

   Huang *et al* [@R9]                                                                                       2010   China                 0.545        0.719        Histopathology       Ma689               --      \>10%              18    9    23    15
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AUC, area under the receiver operating characteristic curve; CA19-9, carbohydrate antigen 19-9; FN, false negative; FP, false positive; MUC1, Mucin1; NA, not available; Se, sensitivity; Sp, specificity; TN, true negative; TP, true positive.

###### 

Characteristics of eligible studies included in prognostic meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                     Year   Country    Type of CCA   No. of patients   Anti-MUC1     Cut-off\                     Follow-up (months)   HR for overall survival\    P value
                                                                                             (positive/high expression)                        (95% CI)                    
  -------------------------- ------ ---------- ------------- ----------------- ------------- ---------------------------- -------------------- --------------------------- ---------
  Higashi *et al* [@R7]      2012   Japan      M-iCCA        63                mAb DF3       \>5% (58)                    \>50                 3.34 (0.43 to 25.8)         0.168

  Huang *et al* [@R9]        2010   China      iCCA          33                Clone Ma689   \>10% (18)                   \>20                 1.89 (0.79 to 4.511)\*      \<0.01

  Park *et al* [@R10]        2009   Korea      CCA           85                Clone Ma695   \>10% (56)                   \>50                 1.211 (0.403 to 3.640)      0.733

  Boonla *et al* [@R12]      2005   Thailand   iCCA          87                Clone Ma695   \>25% (34)                   \>15                 2.19 (1.11 to 4.32)         0.026

  Shibahara *et al* [@R13]   2004   Japan      M-iCCA        27                Mab DF3       \>5% (22)                    \>50                 4.536 (0.292 to 70.336)     0.2797

  Matsumura *et al* [@R15]   2002   Japan      M-iCCA        50                mAb HMPV      \>5% (38)                    \>50                 4.377 (1.517 to 12.629)     0.0063

  Tamada *et al* [@R14]      2002   Japan      CCA           60                MAb DF3       \>20% (46)                   \>50                 1.57 (0.52 to 4.68)**\***   \<0.05

  Higashi *et al* [@R36]     1999   Japan      CCA           39                mAb DF3       \>5% (23)                    \>50                 1.91 (0.52 to 7.03)**\***   \<0.05

  Takao *et al* [@R37]       1999   Japan      CCA           67                Mab DF3       \>25% (47)                   \>50                 2.59 (1.19 to 5.63)         0.016
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*The data were digitised and extracted from the Kaplan-Meier curve using the software designed by Jayne F Tierney and Matthew R Sydes.

CCA, cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; M-iCCA, mass-forming intrahepatic cholangiocarcinoma.

The level of WFA-MUC1 in bile and serum were tested by the approach of ELISA using mAb WFAMY.1E12. The concentration of serum CA19-9 was tested by CA19-9 ELISA kits. The sensitivity, specificity and AUC of each study included in the diagnostic meta-analysis were shown in [table 2](#T2){ref-type="table"}.

Three studies[@R9] investigating the prognostic value of MUC1 for CCA provided the Kaplan-Meier curve, and we digitised and extracted the data of HRs including their corresponding 95% CI from the curve by using the methods described above. The cut-off value to define positive expression of MUC1 (two trials[@R12]: \>25%, one trial[@R14]: \>20%, two trials[@R9]: \>10% and four trials[@R7]: \>5%), the follow-up time (seven trials[@R7]: \>50 months, one trial[@R9]: \>20 months and another one[@R12]: \>15 months) and the antibody of MUC1 were selected for immunochemistry (mAb DF3, Clone Mab DF3, Clone Ma695, Clone Ma689 and mAb HMPV) were inconsistent (as shown in [table 3](#T3){ref-type="table"}).

Primary endpoint: the outcomes of diagnostic meta-analysis {#s3c}
----------------------------------------------------------

Three trials[@R35] including 414 cases of biliary tract carcinoma (59 gall bladder carcinomas and 355 CCA) and 405 subjects with benign biliary diseases investigated the diagnostic capability of WFA-MUC1 level in serum. [Figure 2A](#F2){ref-type="fig"} presented the diagnostic parameters s for serum WFA-MUC1 in an SROC graph. The pooled optimal sensitivity (true positive rate) was 0.76 (95% CI 0.71 to 0.81) and specificity (true negative rate) was 0.72 (95% CI 0.59 to 0.83). The AUC of SROC was 0.77 (95% CI 0.73 to 0.81).

![Summary receiver operating characteristic curve (SROC) for WFA-MUC1 and CA19-9. (A) SROC of serum level of MUC1. (B) SROC of serum level of CA19-9. (C) SROC of biliary level of MUC1. (D) SROC of MUC1 in biliary duct cancer tissue. AUC, area under the curve; MUC1, Mucin1; CA19-9, carbohydrate antigen 19-9; WFA-MUC1, *Wisteria floribunda* agglutinin sialylated-Mucin1.](bmjopen-2018-021693f02){#F2}

As a comparison, three trials[@R34] with 588 subjects with biliary tract carcinoma (73 subjects with gall bladder carcinoma and 515 CCA) and 432 subjects with benign biliary disease evaluated the diagnostic capability of CA19-9 level in serum. [Figure 2B](#F2){ref-type="fig"} presented the diagnostic parameters for serum level of CA19-9 in a SROC graph. The pooled optimal sensitivity was 0.67 (95% CI 0.61 to 0.72) and specificity was 0.86 (95% CI 0.75 to 0.93). The AUC under SROC was 0.75 (95% CI 0.71 to 0.79).

Four trials[@R31] including 209 subjects with benign biliary disease and 416 biliary tract carcinomas (73 gall bladder carcinomas) evaluated the diagnostic capability of biliary level of WFA-MUC1. SROC of biliary WFA-MUC1 was shown in [figure 2C](#F2){ref-type="fig"}. The pooled sensitivity was 0.85 (95% CI 0.81 to 0.89) and specificity was 0.72 (95% CI 0.64 to 0.80). The AUC under SROC was 0.88 (95% CI 0.85 to 0.90). Furthermore, three trials[@R6] inculding 72 subjects with CCA and 119 benign biliary disease used the positive expression of MUC1 in tissue as a criterium to discriminate CCA from benign biliary disease. The diagnostic parameters of positive expression of MUC1 in biliary duct cancer tissue were shown in [figure 2D](#F2){ref-type="fig"}. The pooled sensitivity was 0.72 (95% CI 0.50 to 0.87) and specificity 0.85 (95% CI 0.70 to 0.93). The AUC of SROC was 0.86 (95% CI 0.83 to 0.89).

Secondary endpoint: the outcome of prognostic meta-analysis {#s3d}
-----------------------------------------------------------

Nine studies[@R7] with a total of 511 individuals diagnosed with CCA were eligible for the pooled analysis of OS. As shown in the [figure 3](#F3){ref-type="fig"}, the overall pooled HRs of MUC1 was 2.20 (95% CI 1.57 to 3.01). No heterogeneity among these studies was found (I^2^ **=**0; p=0.869). Subgroup analyses stratified by the histopathological morphology of CCA reveal that the pooled HRs of mass-forming intrahepatic CCA was 4.17 (95% CI 1.71 to 10.17). The pooled HRs of CCA was 1.98 (95% CI 1.37 to 2.85).

![Forest plot of HR evaluating overall survival of patients with resectable CCA. MUC1, Mucin1.](bmjopen-2018-021693f03){#F3}

Risk of bias within studies {#s3e}
---------------------------

Detailed results of the risk of bias assessment for included studies in prognostic meta-analysis were shown in online [supplementary table 1](#SP1){ref-type="supplementary-material"}. As shown in supplementary table 1, one study[@R12] that showed a high risk of bias, six showed[@R7] a low risk of bias and two[@R14] were shown with the unclear risk of bias. Moreover, as demonstrated in [figure 4](#F4){ref-type="fig"}, the result of funnel plots of OS showed no clear indication of publication bias (Egger's test, p=0.661). Selection bias of diagnostic analyses may be caused by two trials including 73 subjects diagnosed with gall bladder carcinoma.[@R34] Detailed items selected for quality assessment of studies included in diagnostic meta-analysis was shown in online [supplementary table 2](#SP2){ref-type="supplementary-material"}.
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![Funnel plot for overall survival.](bmjopen-2018-021693f04){#F4}

Additional analysis {#s3f}
-------------------

Studies conducted by several research groups have concluded that the patients with mass-forming intrahepatic CCA or periductal infiltrating CCA had a worse prognosis than patients with other types of CCA regarding the OS. These types of CCA have higher rates of recurrence after resection.[@R56] In our meta-analysis for prognosis, subgroup analysis stratified by the histopathological morphology of CCA was conducted to reduce the inconsistency caused by the type of CCA. We found that the OS for patients with positive expression of MUC1 was significantly shorter than that of MUC1 negative group. The overall pooled HRs=2.20. For subjects with mass-forming intrahepatic CCA, HRs=4.17. In addition, a sensitivity analysis was performed to investigate the stability of the pooled HRs. As shown in online [supplementary figure 1](#SP2){ref-type="supplementary-material"}, the results of pooled HRs were not affected significantly by each individual study.

Molecular Function (MF), Biological Process (BP) and Reactome Pathways of MUC1 in cancer we searched the GO classification system (<http://www.pantherdb.org/>) to found the Molecular Function, Biological Process and Reactome Pathways of MUC1 in cancer, the search results was summarised in [table 4](#T4){ref-type="table"}.

###### 

The molecular function (MF), biological process (BP) and reactome pathways of MUC1 in cancer

  --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene Ontology MF Complete   p53 binding, transcription coregulator activity, protein binding and RNA polymerase II proximal promoter sequence-specific DNA binding.
  Gene Ontology BP complete   DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator, negative regulation of cell adhesion mediated by integrin, positive regulation of transcription from RNA polymerase II promoter in response to stress, DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest, negative regulation of transcription by competitive promoter binding, regulation of transcription from RNA polymerase II promoter in response to stress, cytokine-mediated signalling pathway, negative regulation of intrinsic apoptotic signalling pathway in response to DNA damage by p53 class mediator, O-glycan processing, positive regulation of histone H4 acetylation and stimulatory C-type lectin receptor signalling pathway
  Reactome pathways           O-linked glycosylation of mucins, Metabolism of proteins, O-linked glycosylation, Defective C1GALT1C1 causes Tn polyagglutination syndrome, diseases of glycosylation, termination of O-glycan biosynthesis, defective GALNT3 causes familial hyperphosphatemic tumorous calcinosis, defective GALNT12 causes colorectal cancer 1, post-translational protein modification, disease, diseases associated with O-glycosylation of proteins.
  --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion {#s4}
==========

As we all known, serum CA19-9 has been widely used as a tumour marker for CCA. However, its diagnostic accuracy is limited since the serum level of CA19-9 can be strongly influenced by the coexisting inflammatory conditions of the biliary tract and this antigen could not be detected in Lewis gene negative individuals.[@R16] The most commonly performed diagnostic method for CCA is biliary cytology, which tests the bile sample from a biliary drainage catheter. However, the sensitivity of biliary cytology is extremely low (20.7%±3.5%) as reported in published study.[@R58] In our meta-analysis of the diagnostic capability of markers for CCA, seven prospective trials[@R12]and a retrospective study[@R9] were eligible for diagnostic analysis that showed that the diagnostic capability of CA19-9 was inferior to other molecules, such as WFA-MUC1.

In the meta-analysis for diagnosis, the diagnostic value of WFA-MUC1 in serum, bile and biliary duct cancer tissue was evaluated and stratified by subgroups of CCA. Two studies[@R35] with three trials (studies reported by Matsuda *et al* [@R55] included two cohorts) assessed the diagnostic accuracy of WFA-MUC1 level in serum, the pooled sensitivity of WFA-MUC1 was 0.76 (95% CI 0.71 to 0.81). The specificity was 0.72 (95% CI 0.59 to 0.83) and the AUC of SROC was 0.77 (95% CI 0.73 to 0.81). While in three studies[@R34] with four trials assessing the diagnostic accuracy of CA19-9 level in serum, the pooled sensitivity of CA19-9 was 0.67 (95% CI 0.61 to 0.72), the specificity was 0.86 (95% CI 0.75 to 0.93) and the AUC of SROC was 0.75 (95% CI 0.71 to 0.79), which means it would bring a severe error into clinical diagnosis.

The diagnostic capability of serum WFA-MUC1 was superior to that of CA19-9 (as the data showed, AUC ~WFA-MUC1~ vs AUC~CA19-9~: 0.77 (95% CI 0.73 to 0.81) vs 0.75 (95% CI 0.71 to 0.79)). The sensitivity rate of WFA-MUC1 was higher than that of CA19-9 ((95% CI 0.76 (0.71 to 0.81) vs 0.67 (95% CI 0.61 to 0.72)); nevertheless, the specificity rate of serum WFA-MUC1 was less than that of CA19-9 ((0.72 (95% CI 0.59 to 0.83) vs 0.86 (95% CI 0.75 to 0.93)). In order to discriminate CCA from benign biliary disease, the combination of these two biomarkers may be applied to improve the diagnostic capability of WFA-MUC1 or CA19-9, as reported by previously published trials.

In the four prospective studies[@R31] with 343 CAA and 73 gall bladder carcinomas and 209 benign biliary diseases, the diagnostic accuracy of WFA-MUC1 in bile was also assessed. The pooled sensitivity of WFA-MUC1 testing was 0.85 (95% CI 0.81 to 0.89) and specificity was 0.72 (95% CI 0.64 to 0.80) and AUC of SROC was 0.86 (95% CI 0.83 to 0.89). The diagnostic capability of bile WFA-MUC1 was better than that of serum WFA-MUC1 (AUC~MUC1\ in\ bile~ vs AUC~MUC1\ in\ serum~: 0.86 (95% CI 0.83 to 0.89) vs 0.77 (95% CI 0.73 to 0.81)), which is consistent with the concept that for most of diseases, the diagnostic molecule levels are different between locally and systemically.

As described above, the level of WFA-MUC1 has significantly higher diagnosis accuracy than CA19-9. Furthermore, the diagnostic accuracy of biliary WFA-MUC1 level was better than that in serum. Therefore, the diagnostic capability of the combined serum CA19-9 and biliary WFA-MUC1 would be better than that of the combination of serum CA19-9 and serum WFA-MUC1 level in discriminating CCA from the benign biliary disease. Such combined measurement would represent a superior diagnostic test for the detection of CCA in daily clinical practice. Unfortunately, as one study[@R55] included in the diagnostic meta-analyses did not provide the detailed cut-off value of serum WFA-MUC1 level, nor CA19-9 level, the optimal cut-off value of SROC cannot be estimated by this meta-analysis.

It has been demonstrated that MUC1 expression in various human tumours is related to invasive tumour progression and a poor patient outcome.[@R10] In the prognostic meta-analysis, pooled analysis of nine retrospective studies[@R7] has shown that positive MUC1 expressed of tissue was a poor prognosis factor for resectable CCA (the pooled HRs was 2.20, 95% CI 1.57 to 3.01), especially for patients with mass-forming intrahepatic CCA (the pooled HRs was 4.17, 95% CI 1.71 to 10.17), which was demonstrated by the subgroup analysis stratified by the morphology of CCA.

It has been reported by publications that around 50%--60% of CCA are identified as perihilar CCA, up to 20% of CCA are distal, 5% of tumours are multifocal and up to 20% of all CCA are intrahepatic.[@R5] Different type of CCA demonstrates various epidemiological, morphological and clinical features. A previous meta-analysis[@R43] identified several prognostic biomarkers (EGFR, MUC1, MUC4 and p27) for resectable CCA, with a small number of subjects in the subgroup of evaluating the prognostic role of MUC1 (four studies including 265 subjects with resectable CCA were included in the analysis evaluating the prognostic value of MUC1 expression in tissue). The sample size of the prognostic meta-analysis in our study was doubled (9 studies including 511 patients with resectable CCA), and our study provided more explicit description and analysis. Subgroup analysis and sensitivity analysis were conducted to get more reliable results. The pooled HRs result in our study showed that overexpression of MUC1 in tissue was a poor prognostic index for resectable CCA, in particular for patients with mass-forming intrahepatic CCA.

Predictive biomarkers could serve as the key point for personalised cancer treatments such as verifying the chemosensitivity of CCA and developing vaccines to CCA. Up to now, VEGFR, EGFR, HER2, MEK and BRAF have been the focus for the studies evaluating molecular targeting therapies for CCA.[@R62] Along with the better understanding of the pathogenesis of CCA mediated by MUC1, MUC1 may become a new focus of targeted therapies for CCA.

The strength and limitation of this study {#s4a}
-----------------------------------------

This meta-analysis, to our best knowledge, is the first study to evaluate the diagnostic value of WFA-MUC1 and prognostic role of MUC1 for human CCA; we obtained data about the prognostic and/or diagnostic capability of WFA-MUC1/MUC1 for CCA from16 trials, which were identified by systematically searching four databases; all subjects with CCA included in this study were diagnosed by pathologist postoperatively. To avoid the possible bias brought by including studies only with reported HRs that may affect the significance of the statistical analysis, we digitised and extracted the HR data from Kaplan-Meier curves in three studies.[@R9] In addition, sensitivity analysis and subgroup analysis, which was stratified by the morphology of CCA, made our results of the pooled HRs more stable. To analyse the diagnostic capability of WFA-MUC1, we separately assessed the diagnostic accuracy of WFA-MUC1 level in serum, in bile and in tissue. A comparison of diagnostic accuracy between WFA-MUC1 level and CA19-9 level in serum, as well as a comparison of diagnostic accuracy between the WFA-MUC1 level in serum and in bile were also conducted in our study, as previously clinical trials described.

While our present study could provide a great amount of useful information, limitations of our study should be kept in mind. First, majority of the subjects included in this meta-analysis were from Asian hospitals (data on prognostic meta-analysis were retrieved from Japan, China, Korea and Thailand; data on diagnostic meta-analysis were from Japan, Thailand, China, Brazil and the UK). There may be biological differences in terms of tumour behaviours among populations from different regions worldwide. The phenomenon has been reported on the mortality of stomach cancer between eastern countries and western countries.[@R63] Second, four different cut-off values of positive MUC1 immunostaining (\>5% of carcinoma cells stained was defined as the cut-off point by four studies, \>10% defined by two studies, \>20% identified by one study and \>25% defined by another two studies) and four different MUC1 antibodies (mAb DF3, Clone Ma689, Clone Ma695 and mAb HMPV) were used in the nine included studies in our prognostic meta-analysis. Lack of consistency on cut-off value and the type of MUC1 antibody used resulted in considerable heterogeneity. Third, in the diagnostic meta-analysis, although majority of subjects in the biliary tract carcinoma group were diagnosed with CCA, a total of 73 subjects with gall bladder carcinomas were included in this group to evaluate the diagnostic capability of biliary level of MUC1 and serum level of CA19-9. Fifty-nine patients with gall bladder carcinomas were included in the evaluation of the diagnostic capability of serum level of WFA-MUC1. The heterogeneity caused by the inconsistency of participants cannot be underestimated since WFA-MUC1 can serve as an independent predictor of hepatocellular carcinoma recurrence.[@R64] It may be useful for discriminating gall bladder carcinoma from benign gall bladder disease. Fourth, given that only seven trials with a small number of patients were eligible for the diagnostic meta-analysis and two of them did not provide the cut-off value of WFA-MUC1 and CA19-9 in serum, we cannot give an estimated optimal cut-off value for WFA-MUC1 level in serum. Finally, all data in our study was retrieved from subjects with resectable CCA or gall bladder carcinoma, there may be some difference in the pathogenesis between resectable and unresectable CCA.

Conclusions {#s5}
===========

This paper highlighted the importance of WFA-MUC1. It has a better diagnostic capability than CA19-9, and the diagnostic capability of the biliary level of WFA-MUC1 was superior to that in the serum. Furthermore, MUC1 could served as a prognosis factor for poor outcomes of resectable CCA, particularly in mass-forming intrahepatic CCA.

Larger, multicentre studies are still needed for better understanding of the molecular pathogenesis of CCA, developing combined kits to conveniently test the serum/biliary level of MUC1 and serum level of CA19-9 in routine clinical practice, providing an optimal cut-off value of WFA-MUC1 with higher diagnostic accuracy for CCA and benefiting the populations from different regions worldwide.
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